Kelly Reveles, Pharm.D., Ph.D.

Kelly R. Reveles, PharmD, PhD, BCPS is an Associate Professor with the Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin and an Adjoint Associate Professor with the Pharmacotherapy Education and Research Center, School of Medicine, The University of Texas Health Science Center at San Antonio. She received her PharmD degree from UT Austin in 2010 and was recently the first graduate of the joint Translational Science PhD program offered by UT Austin, UT Health Science Center San Antonio, UT San Antonio, and UT School of Public Health.

Dr. Reveles’ long-term research goal is to reduce the incidence and improve the outcomes of healthcare-associated infections by designing, testing, and implementing effective clinical strategies. Her current research focus is the prevention and treatment of Clostridioides difficile infections and innovative methods to improve the translation of clinical research findings into practice. Her research approach emphasizes multidisciplinary, collaborative research across the translational spectrum, including basic science, preclinical animal studies,
human clinical studies, and pharmacoepidemiology studies. She is specifically interested in identifying and implementing clinical strategies for the prevention and treatment of C. difficile infection using national data, the impact of drugs and diseases on the gut microbiome, and the development of microbiome-targeted therapies to mitigate these effects. She is the recipient of a 5-year, $3.4 million NIH/National Institute on Aging R01 grant award evaluating the impact of fecal microbiota transplantation on healthy aging in a marmoset model.

Research Interests: 

Clostridium difficile infection, microbiome science, translational science, comparative-effectiveness research, patient-centered outcomes research, and pharmacoepidemiology